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knockdown may have altered the
immune surveillance milieu in the skin
with its complex cytokine patterns and
reduced numbers and function of Tregs,
thereby leading to the increase of NER
mechanisms and subsequent reduction
of DNA damage as measured by CPDs
(Figure 1c, d, and f). In addition, the
CD28 ligands BB-1 and B7 that are
expressed in keratinocytes provide an
important co-stimulatory signal for CD3-
mediated proliferation of T lympho-
cytes, including alloreacting CD4þ T
cells (Koulova et al., 1991; Simon et al.,
1994). This raises the possibility that
T-cell activation by keratinocytes after
UVB exposure may have been inhibited
by in vivo CD28 siRNA knockdown.
In this regard, it is interesting to note
that functional blockade of CD80/CD86
significantly decreased UV-induced
tumor development (Loser et al., 2005).
In any case, further studies are warranted
to determine the precise mechanisms by
which CD28 knockdown leads to increa-
sed NER and decreased DNA damage
and skin alterations.
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TO THE EDITOR
Oral squamous cell carcinoma occur-
ring after allogeneic hematopoietic stem
cell transplantation (HSCT/SCC) is far
rarer than tobacco- and alcohol-related
oral SCCs (common SCCs; Majhail
et al., 2011). Oral HSCT/SCC is clini-
cally and histopathologically close to
common SCCs and has a poor progno-
sis with high morbidity and mortality,
especially in Fanconi patients (Masserot
et al., 2008; Mawardi et al., 2011). It is
not alcohol- and tobacco-related but is
strongly associated with pre-existing
oral lichen planus–like eruption (LPLE;
Demarosi et al., 2005; Majhail et al.,
2011), an early characteristic feature
of chronic graft-versus-host disease
(cGVHD; Imanguli et al., 2008). LPLE
and idiopathic oral lichen planus (OLP)
are clinically and histopathologically
close (Mattsson et al., 1992). We
have previously shown that HSCT/SCC
exhibits a strong p53 expression (Socie
et al., 1998).
Here, we performed a sequential
study of p53 protein and TP53 gene
alterations in 10 patients with oral LPLE
and HSCT/SCC, compared with 10
patients with OLP and 10 patients with
common SCCs. The study aimed to
determine whether specific p53 altera-
tions were present after HSCT, at what
stage they occurred, and whether LPLE
had features of a preneoplastic disease.
The Institutional Ethics Committee
approved this study. According to the
French law, all patients were informedAccepted article preview online 4 September 2013; published online 17 October 2013
Abbreviations: cGVHD, chronic graft-versus-host disease; DNA, deoxyribonucleic acid; FISH, fluorescent
in situ hybridization; HRM-PCR, high-resolution melting PCR; HSCT, hematopoietic stem cell
transplantation; LPLE, lichen planus–like eruption; OLP, oral lichen planus; SCC, squamous cell carcinoma
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that a part of their sample remaining
after the diagnosis could be used for
this research, and they did not oppose
to this. Written informed consents
were obtained according to the Declara-
tion of Helsinki Principles. HSCT
patients included five men and five
women with a mean age of 36 years
(20–56). The initial disease was
Fanconi anemia (n¼4), chronic mye-
loid leukemia (n¼3), acute lymphoblas-
tic leukemia (n¼2), or myelodysplastic
syndrome (n¼ 1). Conditioning regimen
included chemotherapy in all cases and
total-body irradiation in one case. The
median time after HSCT was 93.5 months
(20–270) for LPLE and 146 months
(48–288) for SCC. The median time lapse
between LPLE biopsies and SCC surgical
pieces was 38 months (2–84). No HSCT
patient used alcohol or tobacco.
We compared p53 expression in LPLE
with that in HSCT/SCC samples
using immunohistochemical analysis
(anti-p53 antibody, clone DO7, Dako,
Glostrup, Danemark). All LPLE and 90%
of HSCT/SCC samples showed nuclear
p53 expression (Figure 1a and b).
The mean number of p53þ cells in
four different fields (field¼ 0.196 mm2;
490% epithelial or tumor cells) was
higher in LPLE (299±135) than in OLP
(77.5±37; Po0.001) and increased
between LPLE and HSCT/SCC (1632±
607; Po0.01). The mean number of
p53þ cells was higher in HSCT/SCC
than in common SCC (422±751;
Po0.01). Therefore, a strong p53 expres-
sion was characteristic of the LPLE-HSCT/
SCC sequence after HSCT.
Using laser microdissection to select
AE1/AE3þ (AE1/AE3 antibody, Roche,
Basel, Switzerland) epithelial cells in the
10 LPLE, high-resolution melting PCR
(HRM-PCR), and Sanger sequencing, no
TP53 gene mutation was detected in the
exons 1–10 in any of the 10 LPLE
samples. In the 10 HSCT/SCC samples,
HRM-PCR and sequencing performed
on laser-microdissected AE1/AE3þ
invasive cells detected only one TP53
mutation in exon 6 for patient 6
(Supplementary Figure S1 online).
TP53 mutations were thus absent in
LPLE and rare in HSCT/SCC.
We then assessed whether p53 pro-
tein accumulation in LPLE and HSCT/
SCC could be linked to accumulation of
a phosphorylated form of p53, using the
anti-serine-15-phosphorylated-p53 anti-
body (R&D Systems, Minneapolis, MN).
In all LPLE samples, phospho-serine15-
p53 was expressed in the whole
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Figure 1. p53 and phospho-serine15-p53 protein accumulation in LPLE and HSCT/SCC. (a) LPLE shows basal p53 expression, and HSCT/SCC is positive, whereas
OLP shows no expression, and one case of common SCC is negative; (b) the mean number of p53-positive cells is larger in HSCT/SCC than in LPLE, in LPLE than in
OLP, and in HSCT/SCC than in common SCC; (c) LPLE shows a diffuse epithelial phospho-serine15-p53 expression, and HSCT/SCC is positive, whereas OLP
shows no expression, and common SCC is positive. Scale bars¼200mm in LPLE and OLP (a, c); 500mm (a) or 250mm (c) in HSCT/SCC and common SCC.
(d) The mean number of phospho-serine15-p53-positive cells is higher in common SCC than in OLP and is higher in LPLE than in OLP. *0.01oPo0.05;
**0.001oPo0.01; ***Po0.001. h.p.f., high power field; HSCT, hematopoietic stem cell transplantation; LPLE, lichen planus–like eruption;
NS, not significant; OLP, oral lichen planus; SCC, squamous cell carcinoma.
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epithelium; in 90% of HSCT/SCC sam-
ples, it was expressed by tumor cells; in
80% of OLP samples, no expression
was found (Figure 1c and d). The mean
number of phospho-serine15-p53þ
cells was not significantly different in
LPLE (728±678) and HSCT/SCC
(1687±571; P40.05), nor in HSCT/
SCC versus common SCC (P40.05),
but it was significantly higher in LPLE
than in OLP (0±41; Po0.001).
We also assessed whether TP53 gene
copy-number alterations in LPLE and
HSCT/SCC could explain p53 accumu-
lation, using fluorescent in situ hybridi-
zation. Copy-number alterations were
found in all five LPLE samples studied
and in the five corresponding HSCT/
SCC samples: for LPLE, TP53 haploin-
sufficiency was seen in 27–53% of
epithelial cells in three samples and an
increased TP53 copy number was seen
in 40–65% of epithelial cells in two
samples; for HSCT/SCC, TP53 haploin-
sufficiency was seen in 70–77% of cells
in three samples and an increased TP53
copy number was seen in 45–70% of
cells in two samples (Figure 2). In three
OLP samples, no copy-number altera-
tion was found. Therefore, similar TP53
copy-number alterations were detected
both in LPLE and HSCT/SCC samples.
Taken together, we have shown in a
series of sequential samples of LPLE and
HSCT/SCC that p53 protein accumula-
tion was not linked to TP53 mutation
and that p53 phosphorylation and
TP53 copy-number alterations occurred
early in the oncogenic process, at the
LPLE stage.
The only TP53 mutation was found in
SCC in a patient with HSCT for Fanconi
anemia, a disorder characterized by
genomic instability and defective DNA
repair. The rarity of TP53 mutation
herein confirms previous findings in
three cases of HSCT/SCC showing the
absence of TP53 mutation in exons 5–9
(Zhang et al., 2002). Our results in LPLE
are also in accordance with an in vitro
GVHD model, where keratinocytes
showed no mutations in TP53 (Sloand
et al., 2010).
In the absence of TP53 mutation, p53
phosphorylation could explain p53
accumulation. As phosphorylation of
serine residues on p53 protein stabilizes
p53, limiting its degradation and inhi-
biting nuclear export (Zhang and Xiong,
2001), and as serine15-phosphorylation
is critical in nitric oxide–induced p53
activation in chronic inflammation
(Hofseth et al., 2003), as observed in
cGVHD (Themeli et al., 2010), we
explored phospho-serine15-p53 expre-
ssion. P53 serine15-phosphorylation,
detected in both common SCC and
HSCT/SCC samples, was also found in
LPLE but not in OLP.
TP53 copy-number alterations,
whether TP53 haploinsufficiency or an
increased TP53 allele copy number,
were found in all LPLE-HSCT/SCC seq-
uences, as described in different malig-
nancies, where TP53 allele deletion can
be associated with p53 accumulation
without TP53 mutation (Brito-Babapulle
et al., 2000; Saeki et al., 2011). These
findings are in accordance with the high
rate of genomic instability in oral
mucosa after HSCT (Khan et al., 2010)
and with the common haploinsuffi-
ciency for TP53 due to the loss of
chromosome 17 in keratinocytes in an
in vitro GVHD model (Sloand et al.,
2010). Such genomic instability may be
due to chronic nitric oxide release and/
or to replication stress.
Finally, the demonstration of p53
accumulation, p53 serine15-phosphory-
lation, and TP53 copy-number altera-
tions at the early stage of LPLE, preced-
ing HSCT/SCC, is a novel argument to
consider LPLE as a preneoplastic stage
that requires appropriate care.
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TO THE EDITOR
Human basal cell carcinoma (BCC), the
most common cancer prevailing in the
United States of America, is resistant to
conventional chemotherapy, although
early surgical excision typically results
in cure (Pfeiffer et al., 1990). An in vivo
human BCC xenograft model led to
the recent identification of CD200þ
CD45BCC tumor-initiating cells
(TICs) (Colmont et al., 2013), one of
only 16 human cancer TIC populations
characterized by an in vivo assay
(Colmont et al., 2012). The reproducible
propagation of human BCC in a
xenograft model was dependent upon
the generation of a ‘‘humanized’’
fibrovascular stromal bed in athymic
nude mice, similar to the human
squamous cell carcinoma in vivo assays
(Patel et al., 2012), but additionally
required administration of intraperitoneal
etoposide 1 day before BCC grafting.
We hypothesized that etoposide in this
assay might (1) kill BCC TICs leading
to an underestimation of the true TIC
frequency and/or (2) might result in an
in vivo selection bias favoring resistant
BCC cells including non-TICs.
BCC cells in tissue culture formed
spheroidal colonies that when enumer-
ated correlated with the in vivo TIC
frequency, allowing us to assess the
effect of etoposide on BCC TICs
(Supplementary Material online). Col-
ony numbers and average sizes were
measured before and after etoposide
treatment for 1 hour, 24 hours, and 3
days (n¼6 per condition; Figure 1).
Etoposide exposure for 24 and 72 hours
led to reductions in colony numbers
at 1 mM etoposide (8.5þ 5.2, P¼ 0.01,
t¼4, d.f.¼ 5, r¼0.8 and 4.3þ5.7,
Po0.01, t¼4.6, d.f.¼ 5, r¼ 0.4) but
not at 60mM (P¼0.45 and P¼ 0.12) or
100mM (P¼ 0.05 and P¼ 0.12). There
was no overall difference in mean colony
sizes before, 0.029þ 0.007 mm2 (BCC1
0.0295þ0.0097 mm2, BCC2 0.0295þ
0.0052mm2, BCC3 0.028þ 0.0066mm2),
and after etoposide treatment, 0.028þ
0.006 mm2 (BCC1 0.031þ0.0083 mm2,
BCC2 0.030þ0.0030 mm2, BCC3
0.024þ 0.0040 mm2) (P¼0.65). Hence,
etoposide at clinically relevantAccepted article preview online 11 September 2013; published online 17 October 2013
Abbreviations: BCC, basal cell carcinoma; TIC, tumor-initiating cell
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